187 related articles for article (PubMed ID: 26184119)
1. Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs.
Driessen JH; van Onzenoort HA; Starup-Linde J; Henry R; Burden AM; Neef C; van den Bergh JP; Vestergaard P; de Vries F
Calcif Tissue Int; 2015 Nov; 97(5):506-15. PubMed ID: 26184119
[TBL] [Abstract][Full Text] [Related]
2. Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs.
Driessen JH; van Onzenoort HA; Starup-Linde J; Henry R; Neef C; van den Bergh J; Vestergaard P; de Vries F; Burden AM
Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1017-25. PubMed ID: 26183226
[TBL] [Abstract][Full Text] [Related]
3. Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis.
Driessen JH; Henry RM; van Onzenoort HA; Lalmohamed A; Burden AM; Prieto-Alhambra D; Neef C; Leufkens HG; de Vries F
Calcif Tissue Int; 2015 Aug; 97(2):104-12. PubMed ID: 25894068
[TBL] [Abstract][Full Text] [Related]
4. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture.
Driessen JH; van Onzenoort HA; Henry RM; Lalmohamed A; van den Bergh JP; Neef C; Leufkens HG; de Vries F
Bone; 2014 Nov; 68():124-30. PubMed ID: 25093264
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Cheng L; Hu Y; Li YY; Cao X; Bai N; Lu TT; Li GQ; Li N; Wang AN; Mao XM
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3168. PubMed ID: 30974033
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy.
Douros A; Filion KB; Yin H; Yu OH; Etminan M; Udell JA; Azoulay L
Diabetes Care; 2018 Nov; 41(11):2330-2338. PubMed ID: 30150234
[TBL] [Abstract][Full Text] [Related]
7. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis.
Wang K; Chen Y; Strizek A; Boye K; Gu L; Liu Y; Qu S
Clin Ther; 2019 Oct; 41(10):2057-2065. PubMed ID: 31514971
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?
Luo G; Liu H; Lu H
Br J Clin Pharmacol; 2016 Jan; 81(1):78-88. PubMed ID: 27099876
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues.
Raccah D
Expert Opin Drug Saf; 2017 Feb; 16(2):227-236. PubMed ID: 27924636
[TBL] [Abstract][Full Text] [Related]
12. Effects of diabetes drugs on the skeleton.
Meier C; Schwartz AV; Egger A; Lecka-Czernik B
Bone; 2016 Jan; 82():93-100. PubMed ID: 25913633
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes.
Yen FS; Hou MC; Cheng-Chung Wei J; Shih YH; Hsu CY; Hsu CC; Hwu CM
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1255-1264.e18. PubMed ID: 37331413
[TBL] [Abstract][Full Text] [Related]
14. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
Diabetes Obes Metab; 2014 Jan; 16(1):38-47. PubMed ID: 23829656
[TBL] [Abstract][Full Text] [Related]
15. Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.
Mabilleau G; Mieczkowska A; Chappard D
J Diabetes; 2014 May; 6(3):260-6. PubMed ID: 24164867
[TBL] [Abstract][Full Text] [Related]
16. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.
Bezin J; Gouverneur A; PĂ©nichon M; Mathieu C; Garrel R; Hillaire-Buys D; Pariente A; Faillie JL
Diabetes Care; 2023 Feb; 46(2):384-390. PubMed ID: 36356111
[TBL] [Abstract][Full Text] [Related]
17. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
[TBL] [Abstract][Full Text] [Related]
18. Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study.
Amiche MA; Abtahi S; Driessen JHM; Vestergaard P; de Vries F; Cadarette SM; Burden AM
Arch Osteoporos; 2018 Mar; 13(1):30. PubMed ID: 29552730
[TBL] [Abstract][Full Text] [Related]
19. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
[TBL] [Abstract][Full Text] [Related]
20. Statin but not non-statin lipid-lowering drugs decrease fracture risk: a nation-wide case-control study.
Rejnmark L; Vestergaard P; Mosekilde L
Calcif Tissue Int; 2006 Jul; 79(1):27-36. PubMed ID: 16868664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]